The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Mansour TobaiqyNawal HelmiKathrine MaclureSylvia SaadePublished in: International journal of clinical pharmacy (2023)
High frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.
Keyphrases
- high frequency
- end stage renal disease
- chronic myeloid leukemia
- transcranial magnetic stimulation
- oxidative stress
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- drug induced
- bone marrow
- acute myeloid leukemia
- early onset
- patient reported outcomes
- combination therapy
- oxide nanoparticles
- replacement therapy
- smoking cessation